To be targeted: Is the magic bullet concept a viable option for synthetic nucleic acid therapeutics?

Human Gene Therapy

Volumn 22, Issue 7, 2011, Pages 799-807

  Ogris, Manfred ^a   Wagner, Ernst ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; DNA; DRUG CARRIER; GAMMA CYCLODEXTRIN DERIVATIVE; LIGAND; LIPID; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NUCLEIC ACID; PEPTIDE DERIVATIVE; PLASMID DNA; POLYAMIDOAMINE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYMER; PROTEIN DERIVATIVE; RNA; SMALL INTERFERING RNA;

DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC DISORDER; HUMAN; INFECTION; LIGAND BINDING; METASTASIS; NONHUMAN; REVIEW; SOLID TUMOR; SYSTEMIC THERAPY;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIGANDS; LIPIDS; NEOPLASMS; NUCLEIC ACIDS; PEPTIDES; POLYMERS; RNA, SMALL INTERFERING;

EID: 79960369477     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.065     Document Type: Review

References (86)

1. Aagaard, L., and Rossi, J.J. (2007). RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59, 75-86. (Pubitemid 46770900)
2. Aigner, A. (2006). Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J. Biotechnol. 124, 12-25. (Pubitemid 43816129)
3. Akinc, A., Querbes, W., De, S., et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 18, 1357-1364.
4. Arima, H., Yamashita, S., Mori, Y., et al. (2010). In vitro and in vivo gene delivery mediated by lactosylated dendrimer/alpha-cyclodextrin conjugates (G2) into hepatocytes. J. Control. Release 146, 106-117.
5. Baril, P., Martin-Duque, P., and Vassaux, G. (2010). Visualization of gene expression in the live subject using the Na/I sym-porter as a reporter gene: applications in biotherapy. Br. J. Pharmacol. 159, 761-771.
6. Bartlett, D.W., Su, H., Hildebrandt, I.J., et al. (2007). Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U.S.A. 104, 15549-15554. (Pubitemid 47502954)
7. Behlke, M.A. (2008). Chemical modification of siRNAs for in vivo use. Oligonucleotides 18, 305-319. (Pubitemid 352791344)
8. Besch, R., Poeck, H., Hohenauer, T., et al. (2009). Proapoptotic signaling induced by RIG-I and MDA-5 results in type I in-terferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 119, 2399-2411.
9. Butowski, N., Lamborn, K.R., Lee, B.L., et al. (2009). A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J. Neurooncol. 91, 183-189.
10. Chen, Y.C., Wu, J.Z.J., and Huang, L. (2010). Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol. Ther. 18, 828-834.
11. Cheng, H., Zhu, J.L., Zeng, X., et al. (2009). Targeted gene delivery mediated by folate-polyethylenimine-block-poly(ethylene gly-col) with receptor selectivity. Bioconjug. Chem. 20, 481-487.
12. Davis, M.E., Zuckerman, J.E., Choi, C.H., et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070.
13. De Fougerolles, A.R. (2008). Delivery vehicles for small interfering RNA in vivo. Hum. Gene Ther. 19, 125-132. (Pubitemid 351278372)
14. Elfinger, M., Maucksch, C., and Rudolph, C. (2007). Characterization of lactoferrin as a targeting ligand for nonviral gene delivery to airway epithelial cells. Biomaterials 28, 3448-3455. (Pubitemid 46726633)
15. Elfinger, M., Geiger, J., Hasenpusch, G., et al. (2009a). Targeting of the beta(2)-adrenoceptor increases nonviral gene delivery to pulmonary epithelial cells in vitro and lungs in vivo. J. Control. Release 135, 234-241.
16. Elfinger, M., Pfeifer, C., Uezguen, S., et al. (2009b). Self-assembly of ternary insulin-polyethylenimine (PEI)-DNA nanoparticles for enhanced gene delivery and expression in alveolar epithelial cells. Biomacromolecules 10, 2912-2920.
17. Frohlich, T., and Wagner, E. (2010). Peptide-and polymer-based delivery of therapeutic RNA. Soft Matter 6, 226-234.
18. Gao, J., Liu, W., Xia, Y., et al. (2011). The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32, 3459-3470.
19. Geiger, J., Aneja, M.K., Hasenpusch, G., et al. (2010). Targeting of the prostacyclin specific IP1 receptor in lungs with molecular conjugates comprising prostaglandin I2 analogues. Biomater-ials 31, 2903-2911.
20. Griesenbach, U., and Alton, E.W. (2009). Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv. Drug Deliv. Rev. 61, 128-139.
21. Gunther, M., Wagner, E., and Ogris, M. (2005). Specific targets in tumor tissue for the delivery of therapeutic genes. Curr. Med. Chem. Anticancer Agents 5, 157-171. (Pubitemid 40347989)
22. Guo, P., Coban, O., Snead, N.M., et al. (2010). Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug Deliv. Rev. 62, 650-666.
23. Hatanaka, K., Asai, T., Koide, H., et al. (2010). Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography. Bioconjug. Chem. 21, 756-763.
24. Heidel, J.D., Liu, J.Y., Yen, Y., et al. (2007a). Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin. Cancer Res. 13, 2207-2215. (Pubitemid 46649891)
25. Heidel, J.D., Yu, Z., Liu, J.Y., et al. (2007b). Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase sub-unit M2 siRNA. Proc. Natl. Acad. Sci. U.S.A. 104, 5715-5721. (Pubitemid 47175600)
26. Hodges, B.L., Taylor, K.M., Joseph, M.F., et al. (2004). Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol. Ther. 10, 269-278. (Pubitemid 39117873)
27. Huang, H., Yu, H., Tang, G., et al. (2010). Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials 31, 1830-1838.
28. Hyde, S.C., Pringle, I.A., Abdullah, S., et al. (2008). CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat. Biotechnol. 26, 549-551. (Pubitemid 351668040)
29. Ke, W., Shao, K., Huang, R.,et al. (2009). Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 30, 6976-6985.
30. Klutz, K., Russ, V., Willhauck, M.J., et al. (2009). Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin. Cancer Res. 15, 6079-6086.
31. 131I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol. Ther. 19, 676-685.
32. Kluza, E., van der Schaft, D.W., Hautvast, P.A., et al. (2010). Sy-nergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 10, 52-58.
33. Kormann, M.S., Hasenpusch, G., Aneja, M.K., et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 29, 154-157.
34. Kota, J., Chivukula, R.R., O'Donnell, K.A., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017.
35. Krützfeldt, J., Rajewsky, N., Braich, R., et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685-689.
36. Kumar, M., Yigit, M., Dai, G.P., et al. (2010). Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 70, 7553-7561.
37. Kumar, P., Wu, H., McBride, J.L., et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39-43. (Pubitemid 47037001)
38. Li, J., and Huang, L. (2010). Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond) 5, 1483-1486.
39. Li, S.D., and Huang, L. (2009). Nanoparticles evading the retic-uloendothelial system: role of the supported bilayer. Biochim. Biophys. Acta 1788, 2259-2266.
40. Li, S.D., Chen, Y.C., Hackett, M.J., and Huang, L. (2008a). Tumor-targeted delivery of siRNA by self-assembled nano-particles. Mol. Ther. 16, 163-169.
41. Li, S.D., Chono, S., and Huang, L. (2008b). Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 16, 942-946. (Pubitemid 351587105)
42. Li, W., and Szoka, F.C., Jr. (2007). Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res 24, 438-449. (Pubitemid 46295166)
43. Li, Z., Zhao, R., Wu, X., et al. (2005). Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19, 1978-1985. (Pubitemid 41759743)
44. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med. 49, 453-461. (Pubitemid 351355212)
45. Liu, Y., Huang, R., Han, L., et al. (2009). Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30, 4195-4202.
46. Liu, Y., Li, J., Shao, K., et al. (2010). A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31, 5246-5257.
47. Maeda, H. (2010). Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21, 797-802.
48. McNamara, J.O., 2nd, Andrechek, E.R., Wang, Y., et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015. (Pubitemid 44215395)
49. Medarova, Z., Pham, W., Farrar, C., et al. (2007). In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13, 372-377. (Pubitemid 46376679)
50. Nakagawa, O., Ming, X., Huang, L., and Juliano, R.L. (2010). Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J. Am. Chem. Soc. 132, 8848-8849.
51. Nie, Y., Schaffert, D., Rodl, W., et al. (2011). Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. J. Control. Release. [Epub ahead of print]
52. Ogris, M. (2006). Nucleic acid based therapeutics for tumor therapy. Anticancer Agents Med. Chem. 6, 563-570. (Pubitemid 44697114)
53. Oishi, M., Nagasaki, Y., Itaka, K., et al. (2005). Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepa-toma cells. J. Am. Chem. Soc. 127, 1624-1625. (Pubitemid 40229133)
54. Park, T.G., Jeong, J.H., and Im, S.W. (2006). Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 58, 467-486. (Pubitemid 43949425)
55. Peer, D., Park, E.J., Morishita, Y., et al. (2008). Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630. (Pubitemid 351197066)
56. Philipp, A., Meyer, M., and Wagner, E. (2008). Extracellular targeting of synthetic therapeutic nucleic acid formulations. Curr. Gene Ther. 8, 324-334.
57. Poeck, H., Besch, R., Maihoefer, C., et al. (2008). 5'-Triphosphate- siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 14, 1256-1263.
58. Quan, C.Y., Chang, C., Wei, H., et al. (2009). Dual targeting of a thermosensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release. Nanotechnology 20, 335101.
59. Rozema, D.B., Lewis, D.L., Wakefield, D.H., et al. (2007). Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 104, 12982-12987. (Pubitemid 351737577)
60. Samuel-Abraham, S., and Leonard, J.N. (2010). Staying on message: design principles for controlling nonspecific responses to siRNA. FEBS J. 277, 4828-4836.
61. Schäfer, A., Pahnke, A., Schaffert, D., et al. (2011). By-passing the yin and yang relation of epidermal growth factor receptor (EGFR) mediated delivery: a fully synthetic, EGFR targeted gene transfer system avoiding receptor activation. Hum. Gene Ther. [Epub ahead of print]
62. Schaffert, D., and Wagner, E. (2008). Gene therapy progress and prospects: synthetic polymer-based systems. Gene Ther. 15, 1131-1138.
63. Schaffert, D., Kiss, M., Rodl, W., et al. (2011). Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm. Res. 28, 731-741.
64. Schellmann, N., Deckert, P.M., Bachran, D., et al. (2010). Targeted enzyme prodrug therapies. Mini Rev. Med. Chem. 10, 887-904.
65. Shir, A., Ogris, M., Wagner, E., and Levitzki, A. (2006). EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 3, e6.
66. Shir, A., Ogris, M., Roedl, W., et al. (2011). EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice. Clin. Cancer Res. 17, 1033-1043.
67. Song, E., Zhu, P., Lee, S.K., et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717. (Pubitemid 41716361)
68. Soutschek, J., Akinc, A., Bramlage, B., et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178. (Pubitemid 39545841)
69. Tan, W.B., Jiang, S., and Zhang, Y. (2007). Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28, 1565-1571. (Pubitemid 46039833)
70. Thomas, M., Kularatne, S.A., Qi, L., et al. (2009). Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. N.Y. Acad. Sci. 1175, 32-39.
71. Ulrich, H., Trujillo, C.A., Nery, A.A., et al. (2006). DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb. Chem. High Throughput Screen. 9, 619-632. (Pubitemid 44320411)
72. Uno, Y., Piao, W., Miyata, K., et al. (2011). High-density lipo-protein facilitates in vivo delivery of a-tocopherol-conjugated short-interfering RNA to the brain. Hum. Gene Ther. 22, 711-719.
73. Veedu, R.N., and Wengel, J. (2009). Locked nucleic acid as a novel class of therapeutic agents. RNA Biol. 6, 321-323.
74. Wang, X.L., Xu, R., and Lu, Z.R. (2009). A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. J. Control. Release 134, 207-213.
75. Wolfrum, C., Shi, S., Jayaprakash, K.N., et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157. (Pubitemid 47538115)
76. Wu, G.Y., and Wu, C.H. (1987). Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262, 4429-4432. (Pubitemid 17102799)
77. Wu, S.Y., and McMillan, N.A. (2009). Lipidic systems for in vivo siRNA delivery. AAPS J. 11, 639-652.
78. Yin, H., Lu, Q., and Wood,M. (2008). Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16, 38-45.
79. Yoshizawa, T., Hattori, Y., Hakoshima, M., et al. (2008). Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm. 70, 718-725.
80. Zhang, C., Gao, S., Jiang, W., et al. (2010). Targeted minicircle DNA delivery using folate-poly(ethylene glycol)-polyethylenimine as non-viral carrier. Biomaterials 31, 6075-6086.
81. Zhou, J., Li, H., Li, S., et al. (2008). Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 16, 1481-1489.
82. Zhou, J., Swiderski, P., Li, H., et al. (2009a). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37, 3094-3109.
83. Zhou, J., Shu, Y., Guo, P., et al. (2011). Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 Inhibition. Methods.
84. Zhou, Q.H., Wu, C., Manickam, D.S., and Oupicky, D. (2009b). Evaluation of pharmacokinetics of bioreducible gene delivery vectors by real-time PCR. Pharm. Res. 26, 1581-1589.
85. Zimmermann, T.S., Lee, A.C., Akinc, A, et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114.
86. Zintchenko, A., Susha, A.S., Concia, M., et al. (2009). Drug na-nocarriers labeled with near-infrared-emitting quantum dots (quantoplexes): imaging fast dynamics of distribution in living animals. Mol. Ther. 17, 1849-1856.